Elscint has shown progressin increasing its position in the U.S. market. Historically, theIsraeli-based medical imaging vendor has been stronger in Europethan in the U.S. With scanner sales sagging in both markets, Elscintviews boosting its U.S. share as
Elscint has shown progressin increasing its position in the U.S. market. Historically, theIsraeli-based medical imaging vendor has been stronger in Europethan in the U.S. With scanner sales sagging in both markets, Elscintviews boosting its U.S. share as an opportunity to maintain itsrevenues.
The vendor saw revenue rise 8% in fiscal 1993 (end-December)to $238 million from $221 million in 1992. However, U.S. saleswere up nearly 50% for the year. Net income rose 7% -- not countingthe $4.8 million positive effect of a change in accounting methods-- from $20 million in 1992 to $21.5 million last year.
Breast MRI and Background Parenchymal Enhancement: What a Meta-Analysis Reveals
May 29th 2025Moderate or marked background parenchymal enhancement (BPE) reduces the sensitivity and specificity of MRI for breast cancer detection by more than 10 percent in comparison to scans with minimal or mild BPE, according to a new meta-analysis.
Lunit Unveils Enhanced AI-Powered CXR Software Update
May 28th 2025The Lunit Insight CXR4 update reportedly offers new features such as current-prior comparison of chest X-rays (CXRs), acute bone fracture detection and a 99.5 percent negative predictive value (NPV) for identifying normal CXRs.
Breast MRI and Background Parenchymal Enhancement: What a Meta-Analysis Reveals
May 29th 2025Moderate or marked background parenchymal enhancement (BPE) reduces the sensitivity and specificity of MRI for breast cancer detection by more than 10 percent in comparison to scans with minimal or mild BPE, according to a new meta-analysis.
Lunit Unveils Enhanced AI-Powered CXR Software Update
May 28th 2025The Lunit Insight CXR4 update reportedly offers new features such as current-prior comparison of chest X-rays (CXRs), acute bone fracture detection and a 99.5 percent negative predictive value (NPV) for identifying normal CXRs.
2 Commerce Drive
Cranbury, NJ 08512